Considerations for widespread implementation of blood‐based biomarkers of Alzheimer’s disease
This is my archive
Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer’s disease
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Expanding the use of brief cognitive assessments to detect suspected early-stage cognitive impairment in primary care
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy
Blood-based biomarkers for Alzheimer’s pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times
Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia
